Uncover key drivers, emerging technologies, and competitive movements shaping the rare disease diagnostics market from 2026–2035 with trusted insights from The Business Research Company
What is the estimated market size of the Rare Disease Diagnostics Market by the end of 2030?
The rare disease diagnostics market has experienced substantial expansion over recent years. It is projected to grow from $38.14 billion in 2025 to $41.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. This historical growth can be ascribed to the broader availability of genetic testing, increasing awareness of rare diseases among clinicians, the rising application of molecular diagnostics, the proliferation of specialized diagnostic laboratories, and enhanced access to advanced imaging technologies.
The rare disease diagnostics market is projected to experience substantial expansion in the next few years, with its size anticipated to reach $62.18 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period is primarily fueled by the increasing adoption of personalized medicine, rising investments in genomics research, a growing demand for the early detection of rare diseases, the increasing integration of AI-driven diagnostic tools, and the broadening scope of rare disease screening programs. Furthermore, key trends anticipated in this period encompass the increasing adoption of next-generation sequencing diagnostics, a rising utilization of multi-gene panel testing, the growing integration of advanced imaging in rare disease diagnosis, the expansion of centralized rare disease testing centers, and an enhanced focus on achieving early and accurate diagnoses.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp
What Drivers Are Shaping Future Opportunities In The Rare Disease Diagnostics Market?
The rare disease diagnostics market is projected to grow as a result of the escalating occurrence of rare diseases. These are health conditions impacting a minor fraction of individuals compared to more widespread ailments, frequently demanding specialized diagnostic tools for early and accurate detection. Rare disease diagnostics are instrumental in improving how diseases are managed, enabling the identification of potential therapeutics, and reducing unnecessary or harmful treatments, thereby fostering more effective patient care. For instance, in March 2025, according to Kidney Research UK, an UK-based kidney disease charity, currently, the rare kidney disease landscape includes over 150 distinct conditions, affecting an estimated 70 per 100,000 people, predominantly arising from genetic alterations. Therefore, the surge in rare disease incidence is driving the growth of the rare disease diagnostics market.
Which Segments Are Gaining Traction In The Rare Disease Diagnostics Market?
The rare disease diagnostics market covered in this report is segmented –
1) By Test Type: Genetic Test, General Lab Test, Imaging Test
2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays
3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva
4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease
5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories
Subsegments:
1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing
2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests
3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays
Which Trends Are Expected To Influence The Rare Disease Diagnostics Market In The Upcoming Years?
Leading firms within the rare disease diagnostics market are concentrating on creating sophisticated solutions, like advanced high-sensitivity whole genome sequencing (WGS) platforms, aiming to enhance diagnostic accuracy, broaden the scope of variant detection, and expedite the discovery of intricate rare conditions. These high-sensitivity WGS platforms facilitate an extensive examination of almost all genetic variants responsible for diseases through one test, thus promoting quicker and more precise diagnoses. As an illustration, in April 2023, Centogene GmbH, a German rare disease specialist, introduced CentoGenome. This product is an advanced next-generation sequencing (NGS)-based whole genome sequencing solution specifically engineered for identifying rare and neurodegenerative diseases. The CentoGenome platform provides extensive variant coverage, encompassing Copy Number Variations (CNVs) relevant to spinal muscular atrophy (SMA) and intricate pathogenic variants connected to Gaucher disease (GD) and GBA1-related Parkinson’s disease. Furthermore, CentoGenome integrates PCR-free technology, which helps mitigate sequencing bias in challenging genomic areas, resulting in superior data quality and more profound understanding of coding, regulatory, and intronic regions for improved clinical interpretation.
Who Are The Top-Performing Companies In The Rare Disease Diagnostics Market In Recent Years?
Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Which Region Currently Holds The Largest Share Of The Rare Disease Diagnostics Market?
North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Rare Disease Diagnostics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp
Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2026, By The Business Research Company
Rare Kidney Diseases Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report
Rare Diseases Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Clinical Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model